2013
DOI: 10.1016/j.jad.2013.03.016
|View full text |Cite
|
Sign up to set email alerts
|

Association between major depressive disorder and the norepinephrine transporter polymorphisms T-182C and G1287A: A meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
9
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 30 publications
(10 citation statements)
references
References 38 publications
1
9
0
Order By: Relevance
“…Research suggested that it is essential to inhibit norepinephrine transporter for the synergism of analgesic effect from monoamine transmitter reuptake inhibitors and of opioid drugs [ 13 ]. Cerebral NET activity was associated with agitation of PTSD (posttraumatic stress disorder) patients [ 14 ]. As a membrane-bound G protein-coupled receptor, α 2AR can amplify and transduce the extracellular stimulating signal into cells to trigger intracellular biological reactions.…”
Section: Discussionmentioning
confidence: 99%
“…Research suggested that it is essential to inhibit norepinephrine transporter for the synergism of analgesic effect from monoamine transmitter reuptake inhibitors and of opioid drugs [ 13 ]. Cerebral NET activity was associated with agitation of PTSD (posttraumatic stress disorder) patients [ 14 ]. As a membrane-bound G protein-coupled receptor, α 2AR can amplify and transduce the extracellular stimulating signal into cells to trigger intracellular biological reactions.…”
Section: Discussionmentioning
confidence: 99%
“…The data analysis and statistical methods were carried out according to the methods described in our previous studies (Zhao et al ., , ). All statistical calculations were performed using STATA 12.0 software (Stata Corp., College Station, TX, USA).…”
Section: Methodsmentioning
confidence: 99%
“…A possible association of one variant in the alpha 2A-adrenergic receptor (ADRA2A C-1297G) with milnacipran response was suggested in one study; however, larger sample sizes are required to further validate these results [106]. Another study suggested an association of the genetic variant T-182C in the NET gene (SLC6A2) with better therapy response and an association of the SLC6A2 variant G1287A with a slower therapeutic response onset in depression [107,108]. No distinct treatment guidelines in dependence of genetic polymorphisms are given by the CPIC or DPWG.…”
Section: Serotonin-norepinephrine Reuptake Inhibitorsmentioning
confidence: 99%